What Researchers Did
Researchers reviewed 133 cases of Type II decompression sickness related to high altitudes from U.S. Air Force records to better understand the condition.
What They Found
The study found that 94.7% of cases occurred after altitude chamber training. Common symptoms included joint pain (43.6%), headache (42.1%), and visual disturbances (30.1%). Hyperbaric oxygen therapy successfully resolved symptoms in 97.7% of patients, with only 2.3% having residual problems and no fatalities.
What This Means for Canadian Patients
For Canadian patients, this study reinforces that hyperbaric oxygen therapy is a highly effective treatment for Type II altitude decompression sickness, a condition that can affect aviators, divers, and others exposed to rapid pressure changes. The high success rate of 97.7% suggests that HBOT can lead to excellent recovery and prevent long-term complications for those experiencing this serious condition.
Canadian Relevance
This study was conducted in the U.S. and does not involve Canadian authors or participants. However, decompression sickness is a Health Canada-recognized indication for hyperbaric oxygen therapy, making the findings on HBOT's effectiveness directly relevant to Canadian patients.
Study Limitations
As a retrospective review of past cases from a specific military population, this study lacks a control group and may not represent the broader population or current treatment protocols.